Intraperitoneal α-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211At-MX35 F(ab′)2 - A phase I study

Journal of Nuclear Medicine

Volumn 50, Issue 7, 2009, Pages 1153-1160

  Andersson, Håkan ^a   Cederkrantz, Elin ^a   Bäck, Tom ^a   Divgi, Chaitanya ^b   Elgqvist, Jörgen ^a   Himmelman, Jakob ^a   Horvath, György ^a   Jacobsson, Lars ^a   Jensen, Holger ^c   Lindegren, Sture ^a   Palm, Stig ^a   Hultborn, Ragnar ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Astatine; Clinical study; Dosimetry; Pharmacokinetics; Radioimmunotherapy

Indexed keywords

CARBOPLATIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY MX35 AT 211; N SUCCINIMIDYL 3 (TRIMETHYLSTANNYL) BENZOATE; PACLITAXEL; RADIOISOTOPE; REAGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA RADIATION; ARTICLE; BLADDER; BLOOD SAMPLING; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DOSIMETRY; DRUG ABSORPTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LAPAROSCOPY; OVARY CARCINOMA; PERITONEAL CATHETER; PERITONEAL CAVITY; PERITONEAL FLUID; PRIORITY JOURNAL; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID FUNCTION; TUMOR GROWTH; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; ASTATINE; BODY BURDEN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 67650088549     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062604     Document Type: Article

References (35)

1. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24:571-578.
2. 211At in nude mice with intraperitoneally growing ovarian cancer xenografts: a long-term study. Acta Oncol. 2000;39:741-745.
3. 211At-labelled monoclonal antibody MOv18. Anticancer Res. 2000;20(1A):459-462.
4. 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res. 2001;21(1A): 409-412.
5. Elgqvist J, Andersson H, Back T, et al. α-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342-1350.
6. 211At-MX35 F(ab′)2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006;33:1065-1072.
7. 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-1915.
8. 2. Int J Radiat Oncol Biol Phys. 2006;66:1228-1237.
9. Palm S, Back T, Claesson I, et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69:572-579.
10. Mattes MJ, Look K, Furukawa K, et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res. 1987;47:6741-6750.
11. 2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin Cancer Res. 1997;3:1433-1442.
12. Rubin SC, Kostakoglu L, Divgi C, et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol. 1993;51:61-66.
13. Yin BW, Kiyamova R, Chua R, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3-11.
14. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160.
15. Lindegren S, Andersson H, Back T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol. 2001;28:33-39.
16. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
17. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50:477-484.
18. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
19. Michelsen K. Determination in inulin, albumin and erythrocyte spaces in the bone marrow of rabbits. Acta Physiol Scand. 1969;77:28-35.
20. 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94-101.
21. Crippa F, Bolis G, Seregni E, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686-690.
22. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37:1491-1496.
23. Muto MG, Finkler NJ, Kassis AI, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol. 1992;45:265-272.
24. Nicholson S, Gooden CS, Hird V, et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep. 1998;5:223-226.
25. Stewart JS, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol. 1990;8:1941-1950.
26. Stewart JS, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys. 1989;16:405-413.
27. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007;120:2710-2714.
28. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30-38.
29. Breitz HB, Durham JS, Fisher DR, et al. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. J Nucl Med. 1995;36:754-761.
30. Buijs WC, Tibben JG, Boerman OC, et al. Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med. 1998;25:1552-1561.
31. 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res. 1999;5:953-961.
32. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
33. Hindorf C, Linden O, Tennvall J, Wingardh K, Strand SE. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer. 2002;94(4, suppl):1235-1239.
34. 211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. Nucl Med Biol. 1998;25:351-357.
35. 211At-labeled antibodies with an e-lysyl-3-(trimethylstannyl)-benzamide immunoconjugate. J Nucl Med. 2008;49:1537-1545.